NantKwest Inc. (Nasdaq: NK) announced a presentation of early analysis of the Company’s ongoing Phase II Merkel cell carcinoma study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE